Transcode Therapeutics, Inc. 8-K

What Happened

• TransCode Therapeutics, Inc. (ticker: RNAZ) filed a Current Report on Form 8-K on February 23, 2026 (Item 7.01) disclosing a press release announcing the publication of a manuscript titled "Template-Directed RIG-I Agonist Assembly for Image-guided Targeted Cancer Immunotherapy" in the journal Molecular Imaging and Biology. The press release is furnished as Exhibit 99.1 to the filing.

Key Details

• Filing date: February 23, 2026 (Form 8-K, Regulation FD disclosure).
• Manuscript title: "Template-Directed RIG-I Agonist Assembly for Image-guided Targeted Cancer Immunotherapy."
• Journal: Molecular Imaging and Biology.
• Exhibit: Press release dated February 23, 2026 furnished as Exhibit 99.1 (also noted in Item 9.01 exhibits).

Why It Matters

• Publication of peer-reviewed or journal-listed manuscripts publicly documents TransCode’s scientific progress and can raise visibility with researchers, clinicians, and investors.
• The disclosure complies with Regulation FD reporting requirements and ensures investors have timely access to material scientific developments announced by the company.